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In mice, as in humans, lethal graft-versus-host disease 
(GVHD) with skin involvement often occurs in immu-
noincompetent recipients of donor hematopoietic cells 
in spite of matching at major histocompatibility loci and 
nonreactivity in mixed lymphocyte culture, if donor and 
recipient are disparate at several minor histocompati-
bility loci. In mice, both death and skin disease can be 
prevented by the use of an antiserum containing anti-
bodies to a cell surface glycolipid, asialo GM 1 (ASGM 1 ) . 
Because treatment of only the recipients with anti -asialo 
GM1 substantially reduces the subsequent proliferation 
of infused donor lymphoid cells, we infer that anti-asialo 
GM1 interferes with a host minor-antigen-presenting 
cell, so that donor lymphocytes fail to see minor host 
antigens as immunogenic. Of the tissues examined by 
immunofluorescence microscopy, ASGM 1 was found on 
the epidermal Thy-1+ dendritic cell, on dendritic cells 
in the thymus, and as has been previously described, on 
lung and spleen cells. Following the intravenous admin-
istration of anti-asialo GM~> only the spleen showed an 
obvious change, losing approximately 80% of its 
ASGM1 + cells. Further analysis of spleen cells bearing 
ASGM1 may better define the phenotype of the inferred 
minor antigen-presenting cell and lead to a method of 
improving the outcome of human bone marrow trans-
plantation. 
Graft-versus-host disease (GVHD) that develops in a chi-
mera because of minor histocompatibility antigenic differences 
between donor and recipient fo llows a very different immuno-
logic pathway than graft-versus-host disease due to major his-
tocompatibility differences. Korngold and Sprent [1], using a 
mouse system of biologic fi ltration to effect negative selection 
of donor cells, have demonstrated that donor lymphoid cells 
contain discrete noncross-reactive subgroups ofT lymphocytes 
that recognize minor-histocompatibility antigens in association 
with Class I major-histocompatibility antigens (K or D), but 
not in association with Class II (Ia) antigens. The phenotype 
of the donor cells recognizing forefgn minor-antigens was Thy-
1+, Lyt-1 (weak) Ly2+, Ia- , the phenotype expected of Class I 
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restricted T cells. Thus, the initiators of minor-determinant 
GVHD appeared to be Class I restricted cells, whereas the 
initiators of major-determinant GVHD can be either Class I or 
Class II restricted. Korngold and Sprent have also shown that 
bone marrow-derived cells are necessary for minor-antigen 
presentation, and that host stromal cells were sufficient to 
serve as targets. However the precise identity of the minor-
antigen-presenting cell (or cells) was not determined. The 
essential requirements of such a cell would be that it have on 
its surface minor-antigens and Class I antigens; there being no 
need for Class II antigens. 
Evidence that a host cell (or cells) may be crucial in the 
development of human GVHD has been presented by Lopez et 
a] [2) . They demonstrated that the single best predictor of 
human GVHD was the host's natural killer (NK) cell function, 
measured before transplantation. If the future recipient of 
donor bone marrow had low NK function, GVHD rarely devel-
oped. Conversely, normal recipient NK function predicted a 
very high incidence of GVHD (2]. Natural killer cells are bone 
marrow-derived, express high levels of su:face Class I antigens, 
and do not normally express Class II antigens. Thus, NK cells 
are possible candidates for the putative host minor-antigen-
presenting cell, the presence of which appears to_ be necessary 
for the development of GVHD. It is equally poss1ble, however, 
that NK function merely serves as a marker for a second cell, 
which is the true minor-antigen presenting cell. Another pos-
sibility is that NK cells, through gamma interferon production, 
critically control Class I antigen expression, the density of 
which may determine whether minor-antigens are seen as im -
munogenic or not. 
Utilizing an antibody with profound in vivo activity against 
NK cells (anti-asialo GM1 [a-ASGMJ)) (3], we have found that 
normally lethal GVHD can be prevented in a mouse model of 
hematopoietic transplantation across minor histocompatibility 
barriers with multiple injections of aASGM, [4). Unfortu-
nately, ~ASGM, recognizes an antigen that is on more than 
just NK cells. Natural suppressor cells, monocytes and macro-
phages, precytotoxic T cells, fetal thymocytes, and concana-
valin A-induced suppressor cells are some examples. 
In this report we have begun to address two questions per-
taining to the mechanism of prevention of GVHD by aASGM1: 
1. Are host cells, donor cells, or both, affected by aASGM,? 2. 
Which cell types are affected? 
PROLIFERATION OF DONOR LYMPHOID CELLS IS 
REDUCED IN RECIPIENTS TREATED WITH 
aASGM, BEFORE TRANSPLANTATION 
In our original experiments exploring the effects of systemic 
aASGM, on GVHD, we gave aASGM, to the recipient two days 
before transplantation and to the chimera 4 and 8 days there-
after. Using mice housed in the general animal facility, we 
found that a 3-injection regimen uniformly prevented let hal 
GVHD, that ongoing GVHD (later than day 9, i.e., 2 days after 
histologic onset in the skin) was not affected by aASGM" and 
that 1 injection given to the recipient alone was only variably 
successful in preventing lethal GVHD. 
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Because of our occasiona l success in treating t he recipient 
alone, and because Lopez' human data support a role for the 
recipient's NK cell function [2], we wanted to study the effects 
of aASGM , on an ea rly stage of GVHD . We chose a method 
t hat would quant itate donor lymphoid proliferation in t he host 
15]. Briefl y, th is method uses lymp hoid organ retention of an 
injected radiolabeled DNA -spec ific precurse r, 5[' " l] iodo-2'-
deoxyu ridine {!' 2''I] UdR), as a measure of a llogeneically stim-
ulated proliferation. lt is an in vivo equiva lent to a mixed 
lymphocyte reaction. It measures ea rly events in t he immuno-
biology of GVHD ; recognit ion of host a lloant igens in an im-
munogen ic form by t he injected donor cell s being a prerequisite 
for donor ce ll prolife ration. Table T shows the results from 1 
expe riment and is rep resentative of 2 others. Proliferation was 
significantly less in the chimeras in which the rec ipients had 
been given aASGM, before tra nsplan tation . T hus, t reatment 
of the recipient alone with aASGM, affects t he early stages of 
a gra ft-ve rsus- host (GVH) reaction. The simplest in terpreta-
t ion of these resul ts is t hat a host ce ll bearing ASGM, was 
p hys ically or fun ctionall y deleted, and t hat thi s host ce ll nor-
mally presents minor-antige ns to engra fted a llogeneic lympho-
cytes. Other possibili t ies include the t ri ggering of a suppressor 
circuit by aASG M1 , the elimination of a contra-suppressor 
pathway, an indirect effect on the host's "m icroenvironment," 
and the ASG M 1 ant ige n itself being a restriction molecule. 
In summa ry, aASGM1 does appea r to have an effect on an 
early stage of the GVH reaction, because t reatment of t he 
rec ipient alone reduces the proli feratio n of a llogeneic lympho-
cytes . Our wo rking hypothes is is t hat donor lymphocytes fa il 
to see a lloantigens in an immunogenic context. 
THE SPLEEN, BUT NOT THE LUNG , SKIN, OR 
THYMUS OBVIOUS LY LOSES ASGM1+ CELLS 
AFTER SYSTEMIC aASG M1 TREATMENT 
In order to apprec iate t he morpho logic effects of aASGM1 
t reatment on ASGM1-bearing cell s, we sta ined frozen t issue 
TABLE I. Proliferation of don()r ly mphocy tes in. the spleens of 
irradiated recipien t mice (C57 BL/6J-+LP/J) 
Recipient s 
NR 
aASG M 1 
Mea n % splenic 
l"'' ll UdR uptake 
0.53 ± 0.20 
0. 19 ± 0.09 p < .05 
Dono r lymphoid ce lls were obtai ned from t he ax illa ry, ingu ina l, and 
mesente ric lymph nodes a nd injected in to rec ipients t hat had either 
bee n t reated wit h normal rabbit se rum (NRS) o r aASG M 1· Both groups 
were then letha lly irradiated. Five days later the chimeras were injected 
with 5- flu oro-2' -deoxyuridine (FUdR) to inhibi t t hymidylate synthe-
tase and :JO min late r injected wit h 1/2 11Ci of l '25l] UdR to measure 
a llogeneica lly-stimulated prolife ration. The splee ns were removed 24 h 
late r. Radioactivity was counted a nd exp ressed as a mean % of t he 
injected dose. 
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sections of organs fro m normal mice and from mice systemically 
treated with aASGM1 1 or 2 days previously. Controls incubated 
with normal rabbit se rum followed by f1u oresceinated goat 
ant irabbit immunoglobulin were negative. In t he sp leen, t here 
were ASGM1 positive cells primarily located in the red pulp 
(Fig la,b) . Following systemic aASGM1 t reatment, t here was 
always a reduction in cells staining for ASGM, (Fig l c ) but t he 
magnitude of the change varied among expe riments. We attri-
bute this variabili ty to infectious age nts in the general animal 
faci lity. In order to begin to see which cells were reduced by 
aASG M, t reatment, we did a fluorescence-activated cell sorter 
analysis on disaggregated spleen cells from normal mice or 
aASGM,-treated mice (Fig 2), both of which were housed in a 
laminar fl ow hood and had never been exposed to the general 
animal facility . We found t hat t here was a discrete population 
of lymphoid-sized ce lls t hat stained intensely for ASGM, and 
was markedly reduced following systemic aASGM, (from 4.7% 
to 0.5%). The less brightly staining cells were not as markedly 
diminished following systemic aASGM, (from 8.8% to 7.5 %). 
A cytospin preparation of normal spleen revealed that most of 
t he bright ly staining cells had a lymphoid morphology (Fig ld) , 
whi le many of the duller ce lls had a monocytoid morphology 
(Fig 1 e). Our inte rpretation of t hese findings is that t he variable 
reduction of splenic ASGM1+ cell s probably mirrors ou r vari-
able success at preventing GVHD with only 1 injection of 
aASGM, . If in fact infections increase the number of cells 
bearing ASGM, then either ou r normal dose of aASGM1 may 
be inadequate or the important cells are resistant. Either way, 
host ASGM ,-bearing cells may be t he link in t he known asso-
ciation of infection with more seve re GVHD . 
In the lung, as previously described for disaggregated cells by 
Akagawa et al [6], there were many large cells staining for 
ASGM, (F ig 3). Akagawa eta] have shown that 98+ percent of 
the lung macrophages are ASGM 1+ . (NK ce lls in t he lung are 
presumably a lso ASGM,+.) In epidermal whole moun ts we 
fou nd ASGM,+ dendri t ic cells, t hat could be double- labeled 
with a Thy-1.2, but not with a Ia (Fig 4) . In the t hymus we 
found dendritic appearing ASGM1+ cell s (Fig 5) in both the 
cortex and medulla. Following systemic aASGM, treatment, 
t he lung, skin , and thymus showed no obvious change in num-
ber or morphology of ASGM, -bearing cell s. Although a subpop-
ulation of cell s may have been eliminated from any of these 
organs, or t heir function altered, by the systemic aASGM,, the 
spleen is t he logica l starting point to ask what ASGM ,+ host 
cell type or types are important in the GVH reaction. 
DISCUSSION 
T he mouse model ofGVHD used in these experiments resem-
bles t he usual condi t ions for human bone marrow t ransplan-
tation, in that GVHD deve lops in spite of donor and recipient 
identity at major-histocompatibility loc i and nonreactivity in 
standard mixed lymphocyte cu ltures. Donor T cell s recognize 
F tr. I. Tissue sect ions were incubated fir~t with aASGM, (or norma l rabb it serum as a negative control). washed, and then incubated with a 
lluorescein -ta!-(ged goat a nlirahhi t se rum. No rmal spleen had (a) areas of dispersed brightly staining cells (X80), and (b) a reas of cont iguous 
bri ghtly sta ining ce lls (x80). Spleen sect ions from mice t reated with aASGM, had (c) fewer cells and du lle r staining (X80). Disaggregated normal 
spleen cells s tai ned fo r ASGM, a nd counterstai ned with ethidium brom ide revea led two types of cells: (d) a bri ghtly staining lymphoid cell (Xl28) 
and (e) a less in te nsely sta ined monocytoid ce ll (X200). 
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minor-antigen ic diffe rences in t he recipien t on bone marrow-
derived cell s, proli ferate, a nd ge nerate effecto r cell s (presum -
a bly cytotox ic T cells and suppresso r T cells). Based on t he 
observations in human bone-marrow transplantation by Lopez 
et al [2], t hat t he NK function of t he rec ipient predicted GVHD, 
and ou r observations in mice t hat GVHD can be prevented by 
aASGM 1 injections, t hen t he s implest interpretation is t hat 
NK ce ll s of t he host are importa nt minor-ant igen-presenting 
cells. Severa l cha racteristics of NK cells make t hem as attrac-
t ive as mac rophages as candidates for such a fun ction in GVHD: 
N K cells are radioresistant and are t herefore relat ively enri ched 
in t he host following letha l irradia tion; NK ce lls are rich in 
Class I an t igens, i.e., t he class which restricts recogni t ion of 
minor-histocompatibili ty ant ige ns; a nd systemic aASG M, pro-
fou ndly depresses NK function, a lt hough mac rophage cytotox-
icity is also reduced [7]. 
Because we have not yet shown that host cells are the only 
cells t hat need to be affected by systemic aASGM, to prevent 
GVHD, donor cell s t hat deve lop in t he host may a lso be 
important ta rgets for aASGM,. Theoretica lly, donor macro-
phages should be able to process host minor-ant igens and 
present t hem to donor T cells. In add it ion, pre-cytotoxic donor 
T cells or deve loping donor -derived t hymocytes may be affected 
by systemic aASGM,, since t hey ca rry t he ASGM , a nt ige n. 
Further study should better define t he ce lls affected by systemic 
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FIG 2. Analyses of disaggregat ed 
spleen cells. (a) nonspecific staining with 
secondary reagent a lone, (b) aASGM, 
stai ning of normal spleen cells, and (c) 
aASG M, staining of spleen cells from a 
mouse treated wit h systemic aASGM, 
one day previously. 
FIG 3. Normal lung sections stained 
for ASGM, (x80). 
FIG 4. Epide rmal whole mounts 
stained for ASGM, (X l60) . 
FIG 5. Norma l thymus sect io n s 
stained for ASGM, (X80). 
aASGM,, t heir role in t he immu nobiology of GVHD, and their 
potential relevance to human bone marrow t ransplantation. 
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